Soluble Urokinase Plasminogen Activator Receptor is Associated with Short-Term Mortality and Enhanced Reactive Oxygen Species Production in Acute-on-Chronic Liver Failure

Yunyun Wang  
Wenzhou Medical University First Affiliated Hospital: The First Affiliated Hospital of Wenzhou Medical University

Fengtian Wu  
The First Affiliated Hospital of Zhejiang University

Chao Chen  
Zhejiang University First Affiliated Hospital Institute of Infectious Diseases: Zhejiang University First Affiliated Hospital State Key Laboratory for Diagnosis and Treatment of Infectious Diseases

Lichen Xu  
The First Affiliated Hospital of Zhejiang University

Wei Lin  
The Third Affiliated Hospital of Wenzhou Medical University

Chunhong Huang  
The First Affiliated Hospital of Zhejiang University

Ying Yang  
The First Affiliated Hospital of Zhejiang University

Shanshan Wu  
The First Affiliated Hospital of Zhejiang University

Jinjin Qi  
First Hospital of Zhejiang Province: Zhejiang University School of Medicine First Affiliated Hospital

Hanqin Cao  
The First Affiliated Hospital of Zhejiang University

Guojun Li  
The First Affiliated Hospital of Zhejiang University

Meng Hong  
The First Affiliated Hospital of Zhejiang University

Haihong Zhu (✉ zhuhh72@zju.edu.cn)  
The First Affiliated Hospital of Zhejiang University
Research article

**Keywords:** suPAR, HBV, ACLF, mortality, ROS

**DOI:** [https://doi.org/10.21203/rs.3.rs-131066/v1](https://doi.org/10.21203/rs.3.rs-131066/v1)

**License:** ☕️ 📧 This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Acute-on-chronic liver failure (ACLF) is a comprehensive syndrome characterized by an acute deterioration of liver function and high short-term mortality rates in patients with chronic liver disease.

Objectives: To investigate whether plasma soluble urokinase plasminogen activator receptor (suPAR), a molecule known as a chemokine, is a suitable biomarker for the prognosis of patients with ACLF and the underlying mechanism.

Method: A prospective cohort of 282 patients with ACLF from three hospitals in China was included. 88.4% of the group was hepatitis B virus-related ACLF (HBV-related ACLF). Cox regression was used to assess the impact of plasma suPAR and other factors on 30- and 90-day mortality. Reactive oxygen species (ROS) production were detected to explore the role of suPAR in regulating neutrophil function in HBV-related ACLF.

Result: There was no difference in plasma suPAR levels between HBV-related and non-HBV-related ACLF. Patients with clinical complications had higher suPAR levels than those without these complications. A significant correlation was also found between suPAR and prognostic scores, infection indicators and inflammatory cytokines. Cox's regression multivariate analysis identified suPAR>=14.7ng/mL as a predictor for both day 30 and 90 mortality (Area under the ROC curve: 0.751 and 0.742 respectively), independe nt of the MELD and SOFA scores in patients with ACLF. Moreover, we firstly discovered suPAR enhanced neutrophil ROS production in patients with HBV-related ACLF.

Conclusions: suPAR was a useful independent biomarker of short-term outcomes in patients with ACLF and might play a key role in the pathogenesis.

Trial registration: CNT, NCT02965560. Registered 16 November 2016

Highlights

- suPAR was a useful independent biomarker of short-term outcomes in patients with ACLF
- We firstly discovered suPAR enhanced neutrophil ROS production in patients with HBV-related ACLF, suggesting suPAR might play a key role in the pathogenesis of HBV-related ACLF.

Introduction

Acute-on-chronic liver failure (ACLF) is a complex syndrome defined by the acute onset of liver failure in patients with pre-existing chronic liver disease. It is characterized by high short-term mortality, organ failure, and overwhelming systemic inflammation. Excessive systemic inflammations are believed to be the key driver for the development of ACLF.
Model for End-Stage Liver Disease (MELD), MELD-Na and Child-Turcotte-Pugh (CTP) scores, the conventional scoring systems, do not accurately predict mortality and multi-organ failure (MOF) in ACLF. Recently the CANONIC study developed the CLIF-consortium organ failure (CLIF-C) score, which was demonstrated to be more useful for predicting the outcome of ACLF than conventional scoring systems. However, the scoring process is a little complicated which might impede the understanding of patient conditions in time. Thus, new biomarkers with good predictive value are needed to be discovered.

Urokinase-type plasminogen activator receptor (uPAR) is a part of the plasminogen activator (PA) system. This system is involved in many physiological and pathological processes, including thrombosis, inflammation, tissue remodeling and tumourigenesis. suPAR is a stable protein, released from cleavage of urokinase plasminogen activator receptor (uPAR, CD87) during inflammation. uPAR is mainly expressed on the membranes of circulating immune cells such as monocytes and neutrophils and is closely associated with immune functions such as cell attachment, motility, migration, proliferation, and fibrinolysis. suPAR retains most of activities of uPAR. Moreover, suPAR could bind to podocyte β3 integrin to cause kidney disease and potentiate lipopolysaccharide-induced neutrophil activation.

The production of ROS (reactive oxygen species) is a key factor in the recruitment of activated neutrophils and monocytes to the liver by activated Kupffer cells in liver injury. In addition to recruiting immune cells, ROS itself is also a toxic mediator, through which inflammatory cells can kill targets, such as bacteria, hepatocytes and other organ cells. During the inflammatory response, ROS-induced cell killing mechanisms include the promotion of mitochondrial dysfunction. Through intracellular oxidative stress, cell damage increases and cell contents are released, which further expands the scope of inflammatory damage. ROS also promotes the secretion of cytokines, which in turn leads to an increase in ROS production, leading to a vicious circle and promoting the pathogenesis of liver disease. In addition, resting ROS ≥ 12% in neutrophils predicts the 90-day mortality of patients with liver cirrhosis with high sensitivity and specificity.

The role of suPAR on regulating reactive oxygen species (ROS) production remains unknown. Levels of suPAR are elevated in various infections like HIV infection, malaria, tuberculosis, and sepsis, suggesting its potential ability to predict the outcome of these diseases. This predictive ability might also be useful in ACLF, but few studies have focused on the level of suPAR in patients with ACLF. Moreover, the measurement of suPAR is simple and fast (done in 1 hour 40 min) by a commercial ELISA kit. Thus, we explored whether suPAR was also an appropriate biomarker for determining prognosis in ACLF and its role on regulating ROS productions in neutrophils.

Patients And Methods

Patients
In this prospective study, adult patients suspected to have ACLF and admitted to the Zhejiang University First Affiliated Hospital (Hangzhou, China), Provincial Youth People's Hospital (Hangzhou, China) and Ningbo Yinzhou No.2 Hospital (Ningbo, China) between December 10, 2016 and March 10, 2018 were recruited (Fig. 1). Since the patients included were all from China, the diagnosis of ACLF was based on the Asian-Pacific Association for the Study of the Liver (APASL) criteria: “acute hepatic insult manifesting as jaundice (bilirubin $\geq$ 5 mg/dl) and coagulopathy (INR $> 1.5$) complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease.” Cirrhosis was diagnosed by previous liver biopsy, endoscopy, radiological evidence, or clinical manifestation of liver decompensation. Hepatorenal syndrome (HRS), spontaneous bacterial peritonitis (SBP), and ascites were diagnosed using the criteria established by the International Ascites Club and American Association for the Study of Liver Disease, respectively. Patients with ACLF were then further classified as acute-on-chronic liver failure with multi-organ failure (ACLF-MOF) based on the presence of two or more extra-hepatic organ failures and others as ACLF. Patients were excluded if they were pregnant, diagnosed with acquired immunodeficiency syndrome (AIDS), had any type of malignant tumor, or had undergone liver transplantation. Chronic hepatitis B (CHB) was defined as patients with stable chronic hepatitis B, which was diagnosed by histology or imaging or laboratorial or clinical evidence of cirrhosis or liver fibrosis or long-term liver inflammation together with serum HBsAg positive for more than six months. Healthy controls (HC) had no history or clinical evidence of previous or present illness and with serum HBsAg negative. CHB and HC were gender and age matched with ACLF patients. This study met the principles of the Helsinki Declaration and was approved by the ethics committee of Zhejiang University First Affiliated Hospital. Written consent was acquired from each participant or their legal representative. The study cohort was followed for 90 days after enrolment and the end point was set as either death or liver transplantation.

Sample size calculation

Sample size was calculated by using logrank tests (hazard rate) on PASS software. Tests power was set at $1-\beta = 0.9$, significance level was set at $\alpha = 0.05$ (two sided). Follow up lost rate was considered as 15%.

suPAR and cytokine measurement

Whole blood samples from participants were collected within two days after study enrollment. After centrifugation, plasma was obtained and stored immediately at -80 °C. Plasma samples (25µL) were used to measure suPAR using an enzyme-linked immunosorbent assay (ViroGates, Denmark), and 20µL of plasma sample was used to measure cytokines using a multiplex panel (Bio-Rad, Hercules, CA), according to the manufacturer’s instructions. The detection limits were in the supplementary methods (Appendices).

Oxidative Burst Assays
100µL of whole blood samples from HBV-related ACLF were pre-incubated with suPAR (50 ng/mL, R&D USA) or PBS for 45 minutes at 37 °C in 5% CO2. Next, all samples were incubated with heat-inactivated *E. coli* (8*10^7 cfu/mL) in 96-well plates for 30 minutes. Then the cells were harvested for CD16-PerCP-eFluorTM710 (Biolegend, USA) staining and oxidative burst assessment using an ROS assay kit (Genecopoeia, MD, USA) and were analyzed by a LSRFortessa cytometer (BD bioscience, USA) according to the manufacturer’s instructions.

**Statistical analysis**

Descriptive statistics were expressed as counts [%] and mean ± standard deviation (SD). Continuous data with a non-normal distribution were shown as median (interquartile range; IQR). Baseline characteristics were compared between patients with ACLF and ACLF-MOF by using the Mann-Whitney U test for continuous variables or Fischer’s exact/Pearson’s χ² test for categorical variables. Spearman’s rank correlation analysis was conducted to investigate associations between plasma suPAR concentration and laboratory and clinical data. Due to the unavailability of data in some patients, this correlation analysis was not performed on all patients. Cox univariate and a further multivariate analysis were conducted to distinguish variables highly correlated with mortality. Odds ratios (ORs) and 95% confidence intervals (CIs) were determined for each variable. The ability to predict mortality was calculated by receiver operating characteristic curve (ROC curve). Kaplan Meier survival curves were also developed. Loss of follow-up would also be included in the survival analysis. Comparisons between paired groups were analyzed by the Wilcoxon signed-rank test. All statistical tests were two-sided and *P* < 0.05 was considered statistically significant.

**Results**

**Patient characteristics**

The estimated smallest sample size was 94. After screening, 282 patients with ACLF who fulfilled the inclusion and exclusion criteria were recruited into the study (Fig. 1). The comparison of baseline characteristics of these patients with or without MOF is shown in Table 1. suPAR and baseline characteristics was measured in all participants. Plasma suPAR at admission was significantly higher in patients with MOF than those without MOF (11.9 (9.1–15.5) vs. 16.4 (11.5–24.0) ng/mL; *p* < 0.001, Table 1). Significant differences between the two groups were also found for the presence of some clinical events such as HRS and hepatic encephalopathy (HE), laboratory data such as white blood cell count (WBC), international normalized ratio (INR) and total bilirubin (Tbil), and prognostic scoring systems such as CTP, MELD and SOFA scores. All patients were followed at the end of the point.
Table 1
Baseline characteristics of ACLF patients.

|                      | (A) ACLF (n = 216) | (B) ACLF-MOF (n = 66) | (C) CHB (n = 14) | (D) HC (n = 14) | p-value A vs B |
|----------------------|--------------------|-----------------------|-----------------|----------------|---------------|
| **Age (years), Mean (± SD)** | 47.1 ± 12.6        | 46.4 ± 13.5           | 43.1 ± 14.3     | 42 ± 10.1      | 0.69          |
| **Male (%)**         | 185 (85.6)         | 57 (86.4)             | 12 (85.7%)      | 12 (85.7%)     | 0.88          |
| **Etiology**         |                    |                       |                 |                | 0.07          |
| HBV (%)              | 191 (88.4)         | 64 (97)               | 14 (100)        | -              |               |
| Others (%)           | 25 (11.6)          | 2 (3)                 | -               | -              |               |
| **Clinical feature** |                    |                       |                 |                |               |
| Ascites (%)          | 170 (78.7)         | 50 (75.8)             | -               | -              | 0.61          |
| Cirrhosis (%)        | 110 (50.9)         | 31 (47.0)             | -               | -              | 0.57          |
| UGIB (%)             | 18 (8.3)           | 8 (12.1)              | -               | -              | 0.35          |
| HRS (%)              | 5 (2.3)            | 9 (13.6)              | -               | -              | < 0.001       |
| HE (%)               | 7 (3.2)            | 24 (36.4)             | -               | -              | < 0.001       |
| SBP (%)              | 9 (4.2)            | 6 (9.1)               | -               | -              | 0.12          |
| Bacterial or fungal infection (%) | 23 (10.6)         | 12 (18.2)             | -               | -              | 0.10          |
| Sepsis (%)           | 1 (0.5)            | 2 (3.0)               | -               | -              | 0.27          |
| **Laboratory data**  |                    |                       |                 |                |               |
| suPAR (ng/mL), Median (IQR) | 11.9 (9.06–15.5) | 16.4 (11.4–23.6)     | 2.8 (2.2–4.0)  | 2.3 (2.0–2.9) | < 0.001       |
| WBC (x 10⁹/L), Median (IQR) | 6.2 (4.8–8.7)     | 8.1 (6.1–12.6)       | 5.1 (4.3–6.1)  | 5.4 (4.2–6.8) | < 0.001       |
| Platelets (x 10⁹/L), Median (IQR) | 101 (72–140)      | 122 (81–177)         | 150 (116–200)  | 160 (110–231) | 0.05          |

ACLF acute-on-chronic liver failure, ACLF-MOF ACLF complicated with multi-organ failure, CHB chronic hepatitis B, HC healthy controls, UGIB upper gastrointestinal bleeding, HRS hepatorenal syndrome, HE hepatic encephalopathy, SBP spontaneous bacterial peritonitis, WBC white blood cell count., INR international normalized ratio, CTP Child–Turcotte-Pugh, MELD Model for End-stage Liver Disease, SOFA sequential organ failure assessment.
Baseline plasma suPAR levels and association with ACLF disease progression

There was no difference in plasma suPAR levels between HBV-related and non-HBV-related ACLF (p > 0.05, Appendices, Fig. A. 1). We then determined plasma suPAR among HC, CHB and ACLF and found out suPAR levels in patients with ACLF were markedly higher than those with HC and CHB. (Fig. 2a, 12.16 (7.61–17.57) vs. 2.3 (2.00-2.89) vs 2.7 (2.16-4.00) ng/L; p < 0.001). However, no difference was shown between HC and CHB. We then further compared plasma suPAR levels in ACLF patients with or without complications at admission or during the follow-up period. At admission, patients with HE, HRS, UGBI or infection had higher suPAR levels than those without these complications. Differences in plasma suPAR levels were most pronounced in patients with HRS (30.15 (13.57–36.35) vs. 12.30 (9.33–16.46) ng/L; p < 0.001). (Fig. 2b). There was no statistically significant difference in suPAR levels between patients with or
without SBP, ascites, cirrhosis. (Appendices, Fig. A. 1). Patients exhibiting circulatory failure during follow-up also showed significantly higher suPAR levels than patients without circulatory failure (Fig. 2b).

Aside from clinical features, significant correlations with plasma suPAR were also found for clinical laboratory data and prognostic scores (Table 2). All three prognostic scores were correlated with suPAR levels; the strongest correlation was found with the MELD \( (r = 0.421, p < 0.001) \) (Table 2). Among the laboratory data, various infection-immunity related data showed a positive association with suPAR levels, including the incidence of bacterial or fungal infection, WBC and PCT. Interestingly, in white blood cells, suPAR was positively correlated with the percentage of neutrophils but did not correlate with the percentage of monocytes. At the same time, suPAR was also negatively correlated with HBcAb and the percentage of lymphocytes, indicating that suPAR was positively correlated with innate immunity, but negatively correlated with adaptive immunity in patients with HBV-related ACLF. As systemic inflammation seemed to be the driver for the development of organ failure in ACLF \(^2\), we also investigated whether the concentration of plasma suPAR was associated with plasma inflammatory cytokines in patients with ACLF. After identifying 27 cytokines in 40 patients, a strong correlation was found between two chemokines, MIP1beta and IL-8, and plasma suPAR levels \( (r = 0.453, p = 0.007; r = 0.448, p = 0.003, \) respectively) (Table 2). The rest of the cytokines were either not significantly associated or undetectable (Supplementary, Fig. A.1). Significant correlations were also found between suPAR and liver-related data, kidney-related data, and thyroid-related data, but not heart-related data (Table 2).
Table 2
Association of clinical parameters and prognostic scoring systems with serum suPAR concentrations

| Variable                     | Correlation coefficient with serum suPAR (r) | p-value | Number of patients |
|------------------------------|---------------------------------------------|---------|--------------------|
| Age                          | 0.203**                                     | 0.001   | 282                |
| Infection-immunity data      |                                             |         |                    |
| Bacterial or fungal infection| 0.118*                                      | 0.04    | 282                |
| HBcAb                        | -0.182**                                    | 0.003   | 261                |
| WBC                          | 0.306***                                    | <0.001  | 282                |
| Neutrophil (%)               | 0.250***                                    | <0.001  | 271                |
| Monocyte (%)                 | 0.065                                       | 0.28    | 271                |
| Lymphocyte (%)               | -0.327***                                   | <0.001  | 271                |
| PCT                          | 0.205**                                     | 0.008   | 166                |
| Liver-related data           |                                             |         |                    |
| ALT                          | 0.036                                       | 0.55    | 282                |
| Albumin                      | -0.098                                      | 0.101   | 282                |
| Bilirubin                    | 0.287***                                    | <0.001  | 282                |
| INR                          | 0.281***                                    | <0.001  | 282                |
| Heart-related data           |                                             |         |                    |
| MAP                          | -0.015                                      | 0.80    | 282                |
| hsTnI                        | 0.161                                       | 0.080   | 119                |
| Kidney-related data          |                                             |         |                    |

HBcAb antibody against HBV core, PCT procalcitonin, CRP C-reactive protein, MIP1beta macrophage inflammatory protein 1-beta, INR international normalized ratio, MAP mean arterial pressure, hsTnI hypersensitive troponin I, GFR glomerular filtration rate, T3 Total triiodothyronine, FT3 free triiodothyronine. CTP Child–Turcotte-Pugh, SOFA sequential organ failure assessment, MELD Model for End-stage Liver Disease, UGIB upper gastrointestinal bleeding, WBC white blood cell count. *p < 0.05, **p < 0.01, ***p < 0.001
# Variable correlation coefficient with serum suPAR \( (r) \)  

| Variable    | Correlation coefficient with serum suPAR \( (r) \) | \( p \)-value | Number of patients |
|-------------|---------------------------------------------------|---------------|-------------------|
| GFR         | -0.290**                                          | <0.001        | 270               |
| Creatinine  | 0.219***                                          | <0.001        | 282               |
| Sodium      | -0.221***                                         | <0.001        | 282               |

**Thyroid-related data**

| Variable | Correlation coefficient with serum suPAR \( (r) \) | \( p \)-value | Number of patients |
|----------|----------------------------------------------------|---------------|-------------------|
| \( T_3 \) | -0.356***                                          | <0.001        | 254               |
| \( FT_3 \) | -0.270***                                          | <0.001        | 254               |

**Scores**

| Score | Correlation coefficient with serum suPAR \( (r) \) | \( p \)-value | Number of patients |
|-------|----------------------------------------------------|---------------|-------------------|
| CTP   | 0.183**                                            | 0.002         | 282               |
| MELD  | 0.425***                                           | <0.001        | 282               |
| SOFA  | 0.356***                                           | <0.001        | 282               |

HBcAb antibody against HBV core, PCT procalcitonin, CRP C-reactive protein, MIP1beta macrophage inflammatory protein 1-beta, INR international normalized ratio, MAP mean arterial pressure, hsTnI hypersensitive troponin I, GFR glomerular filtration rate, T3 Total triiodothyronine, FT3 free triiodothyronine. CTP Child—Turcotte-Pugh, SOFA sequential organ failure assessment, MELD Model for End-stage Liver Disease, UGIB upper gastrointestinal bleeding, WBC white blood cell count. *\( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \)

## Survival analysis

During the 30-day follow-up, sixty-two (22.0%) patients died and thirty-four (12.1%) received a liver transplant. During the 90-day follow-up, eighty-two (29.1%) patients died and forty-one (14.5%) underwent liver transplantation.

Baseline plasma suPAR increased in patients who died or underwent transplant \( (n = 123) \) during the 90-day follow-up compared to those who survived without liver transplantation \( (n = 159) \) \( (16.03 (11.65-23.70) \text{ vs. } 11.14 (8.41-14.14) \text{ ng/L, } p < 0.001; \text{ Fig. 2b}) \).

The optimal cut-off point for plasma suPAR in predicting 90-day mortality was 14.7 ng/mL, as calculated by the Youden Index. Based on this optimal cut-off point, Kaplan-Meier curves significantly indicated 30- and 90-day mortality for patients with ACLF. Intriguingly, the effect of suPAR levels on the mortality was significantly larger in patients without cirrhosis or with HE (Fig. 3). The 30-day mortality of patients with both ACLF and cirrhosis was not impacted as much as the 90-day mortality by high suPAR levels (Fig. 3). During 90-day follow-up, patients with high suPAR (suPAR \( > = 14.7 \text{ ng/mL} \)) and with HE had the highest mortality while ACLF patients with low suPAR and without HE had the lowest mortality (Fig. 3).
Correlations between clinical features/laboratory data and short-term mortality were analyzed by univariate Cox regression (Appendices, Table A. 1). Results showed that suPAR was significantly associated with both 90-day and 30-day mortality (p < 0.001). Variables with statistically significant (p < 0.05) in univariate regression analyses and age were included in multivariate models. To explore whether serum suPAR was correlated with the short-term mortality independently of the prognostic scores, suPAR was separately evaluated with MELD and SOFA scores in multivariate analysis. Variables included in two prognostic scores would be ruled out from multivariate models in order avoid collinearity.

Cox's regression multivariate analysis using the forward step-wise selection method identified suPAR ≥ 14.7 ng/mL and WBC ≥ 6.6·10^9, together with MELD ≥ 23.1 SOFA ≥ 9.5, as the independent predictors of both day 90 and day 30 mortality (Table 3). These models were validated by bootstrapping.
Table 3
Multivariate Cox regression models for short-term mortality in ACLF patients

|                              | HR (95% CI)     | p - value  | Bootstrapping p - value |
|------------------------------|-----------------|------------|-------------------------|
| **Mortality at 30 days**     |                 |            |                         |
| Model 1: MELD score          |                 |            |                         |
| MELD ≥ 23.1                  | 3.62 (1.93–6.76) | < 0.001    | 0.001                   |
| suPAR ≥ 14.7                 | 3.72 (2.15–6.41) | < 0.001    | 0.001                   |
| WBC ≥ 6.6                    | 1.96 (1.10–3.51) | 0.02       | 0.016                   |
| Model 2: SOFA score          |                 |            |                         |
| SOFA ≥ 9.5                   | 3.18 (1.67–6.10) | < 0.001    | 0.001                   |
| suPAR ≥ 14.7                 | 3.52 (2.02–6.13) | < 0.001    | 0.001                   |
| WBC ≥ 6.6                    | 2.03 (1.13–3.67) | 0.02       | 0.017                   |
| Model 3 Other Clinical Data  |                 |            |                         |
| suPAR ≥ 14.7                 | 4.77 (2.78–8.19) | < 0.001    | 0.006                   |
| Sepsis                       | 7.48 (2.25–24.85) | 0.001      | 0.009                   |
| Cirrhosis                    | -               | 0.25       | 0.30                    |
| UGIB                         | -               | 0.40       | 0.78                    |
| HRS                          | -               | 0.09       | 0.15                    |
| **Mortality at 90 days**     |                 |            |                         |
| Model 1: MELD score          |                 |            |                         |
| MELD ≥ 23.1                  | 3.19 (1.88–5.41) | < 0.001    | 0.001                   |
| suPAR ≥ 14.7                 | 3.02 (1.90–4.81) | < 0.001    | 0.001                   |
| WBC ≥ 6.6                    | 1.97 (1.21–3.21) | 0.007      | 0.008                   |
| Age ≥ 46.5                   | 2.51 (1.54–4.08) | < 0.001    | 0.003                   |
| Model 2: SOFA score          |                 |            |                         |
| SOFA ≥ 9.5                   | 2.54 (1.51–4.29) | < 0.001    | 0.001                   |
| suPAR ≥ 14.7                 | 2.89 (1.78–4.69) | < 0.001    | 0.001                   |

UGIB upper gastrointestinal bleeding, HRS hepatorenal syndrome, WBC white blood cell count, MELD Model for End-stage Liver Disease, SOFA sequential organ failure assessment.
| HR (95% CI) | p - value | Bootstrapping p - value |
|-------------|-----------|-------------------------|
| WBC ≥ 6.6   | 2.00 (1.22–3.27) | 0.006                   | 0.007 |
| Age ≥ 46.5  | 2.73 (1.68–4.45)  | < 0.001                 | 0.001 |

Model 3 Other Clinical Data

| suPAR ≥ 14.7 | 4.52 (2.87–7.14) | < 0.001                 | 0.003 |
| Sepsis       | 7.33 (2.21–24.32) | 0.001                   | 0.02  |
| Cirrhosis    | -                  | 0.10                    | 0.15  |
| UGIB         | -                  | 0.24                    | 0.58  |
| HRS          | -                  | 0.12                    | 0.24  |

UGIB upper gastrointestinal bleeding, HRS hepatorenal syndrome, WBC white blood cell count., MELD Model for End-stage Liver Disease, SOFA sequential organ failure assessment.

Moreover, analysis of the area under the receiver operating characteristic curve (ROC-AUC) revealed that suPAR may be a useful predictor for both 30- and 90-day mortality in ACLF patients (0.751 and 0.742, respectively) (Table 4).

| ROC area (95% CI) |
|-------------------|
| Mortality at 30 days |
| suPAR             | 0.751 (0.684–0.817) |
| MELD              | 0.732 (0.658–0.807) |
| SOFA              | 0.763 (0.698–0.828) |
| Mortality at 90 days |
| suPAR             | 0.742 (0.680–0.805) |
| MELD              | 0.729 (0.663–0.795) |
| SOFA              | 0.726 (0.662–0.789) |

MELD Model for End-stage Liver Disease, SOFA sequential organ failure assessment.

suPAR enhanced neutrophil ROS production.
ROS plays a key role in ACLF pathogenesis\textsuperscript{26}. To better understand the role of suPAR in ACLF, we applied suPAR to circulating neutrophils from patients with HBV related-ACLF under stimulation of \textit{E. coli}. There was enhanced ROS production in neutrophils after suPAR addition, suggesting elevated serum suPAR levels promote disease progress in HBV related-ACLF (Fig. 4, p < 0.05).

**Discussion**

In this study, we investigated the role of suPAR in predicting short-term outcomes in patients with ACLF. Results showed that suPAR was an independent predictor for the short-term mortality of patients with ACLF. One of the underlying mechanisms might be suPAR enhanced neutrophil ROS production in ACLF.

Bacterial infection is a main predisposing factor for the onset of ACLF\textsuperscript{27}, and the subsequent excessive inflammatory response is the driving factor for the occurrence of MOF. Our study showed the suPAR is associated with several infection-immunity-related indicators in patients with ACLF, suggesting that suPAR may play an important role in the pathogenesis of ACLF. We found a mild correlation between suPAR and bacterial or fungal infection, the latter reportedly causing the release of suPAR from the monocyte membrane\textsuperscript{28}. Because this association was mild, it implies that there were other factors driving the production of circulating suPAR.

Recently, patients with ACLF were found to have higher suPAR levels than healthy controls. Because the ACLF patients displayed no signs of bacterial infection, it was assumed that either liver-derived factors induced uPAR cleavage from various immune cells, or that uPAR was shed from damaged or activated hepatocytes\textsuperscript{29}. Since uPAR was not detected on damaged hepatocytes,\textsuperscript{29} the latter assumption may be excluded.

Excessive systemic inflammation is a notable feature of ACLF. suPAR, which acts as a chemokine, has been shown to play an important role in the immune system\textsuperscript{30}. In addition, our study discovered a strong positive relationship between suPAR and two chemokines, MIP1beta and IL-8. This indicates that hepatic inflammation may be linked to suPAR release. However, no correlation was found between suPAR and other cytokines, such as IL-6 and IL-1. IL-6 and IL-8 have both been associated with short-term mortality in ACLF patients\textsuperscript{31}. Since IL-1 and IL-6 were potent inducers of the acute phase response\textsuperscript{31}, this phenomenon may imply that suPAR was not directly involved in the onset of ACLF but may correlate with the later accumulation of immune cells in the liver. In addition, our study found suPAR increased ROS production in neutrophils in patients with ACLF.

(suPAR) is newly emerged a circulating factor that could predict the development and progression of chronic kidney disease CKD\textsuperscript{32}, such as focal segmental glomerulosclerosis (FSGS)\textsuperscript{16,33}, which is characterized by proteinuria and associated with renal failure and kidney transplantation\textsuperscript{34}. The underlying mechanism has been demonstrated that the circulating suPAR activates $\alpha_v\beta_3$ integrin on podocyte membrane and leads to podocyte foot process effacement and damage glomerular barrier function\textsuperscript{16}. APOL1 risk variants could synergize this process\textsuperscript{35}. Such role of suPAR in kidney disease
might explain our finding that the differences in plasma suPAR levels, when compared ACLF with or without complications, were most pronounced with hepatorenal syndrome (HRS).

In ACLF, the excessive immune response is due to overactivation of the innate immune system but not the adaptive immune system. Neutrophils and monocytes increased, but lymphocytes decreased, and the neutrophil-to-lymphocyte ratio (NLR) was positively associated with 90-day mortality.\(^3\)\(^1\) Our study found that suPAR was positively associated with the percentage of neutrophil, indicating that suPAR is mainly derived from circulating neutrophils. In addition, the inverse relationship of suPAR to the percentage of lymphocytes and HBcAbs suggested that suPAR might be associated with the weak adaptive immunity of patients with ACLF. However, associations of suPAR with the percentage of those white cells were weak, indicating other factors such as the activities of immune cells might also influence the release of suPAR.

Patients with severe liver fibrosis have been shown to exhibit higher serum suPAR levels compared with patients with mild fibrosis.\(^3\)\(^6\),\(^3\)\(^7\) However, we found no difference in plasma suPAR levels between ACLF patients with or without cirrhosis. This may be because the immune response in patients with ACLF is so strong that the impact of fibrosis on suPAR was masked. K-M survival analysis revealed the interesting phenomenon that suPAR predicted the short-term outcome of patients with ACLF but without cirrhosis better than those with both ACLF and cirrhosis. This may be because the immune cells are in prolonged contact with suPAR, and these cells become insensitive to suPAR stimulation in patients with cirrhosis.

Since suPAR is easy and fast to measure compared with the complicated scoring system, it has the potential to replace the complicated scoring systems in the busy emergency department or is incorporated to those scores to improve the predicting ability.

There are some limitations in our study. First, as was mentioned above, plasma suPAR levels were significantly higher in patients with renal failure compared to those without renal failure. In addition to the possibility that the kidneys secreted extra suPAR, it is also possible that renal failure made it difficult to remove suPAR from the circulation. Further studies are needed to determine why suPAR was elevated in patients with renal failure and whether the predictive ability of suPAR was influenced by those patients. Second, the treatments were not uniform. Due to variation between physician practices, doses and treatment strategies may differ. For example, the timing and dose of vasopressors administered might be different during circulatory failure in different patients treated by different doctors. Finally, we did not deeply explore the underlying mechanism of how suPAR enhanced neutrophil ROS production in patients with ACLF. Further study should focus on this point.

### Abbreviations

ACLF acute-on-chronic liver failure, HBV-related ACLF hepatitis B virus-related ACLF, suPAR soluble urokinase plasminogen activator receptor, ACLF-MOF ACLF complicated with multi-organ failure, CTP Child—Turcotte-Pugh, SOFA sequential organ failure assessment, CRP C-reactive protein, HE hepatic
encephalopathy, INR international normalized ratio, MELD Model for End-stage Liver Disease, SIRS systemic inflammatory response syndrome, UGIB upper gastrointestinal bleeding, WBC white blood cell count, PCT procalcitonin, MIP1 beta macrophage inflammatory protein 1-beta, MAP mean arterial pressure, hsTnI hypersensitive troponin I, GFR glomerular filtration rate, T3 Total triiodothyronine, FT3 free triiodothyronine.

Declarations

Ethics approval and consent to participate

This study met the principles of the Helsinki Declaration and was approved by the ethics committee of Zhejiang University First Affiliated Hospital. Written consent was acquired from each participant or their legal representative.

Consent for publication

Not applicable

Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare that they have no competing interests

Funding

Science and Technology Major Projects of Zhejiang Province, No. 2018C04016: design of the study; interpretation of data and in writing the manuscript.; National Science and Technology Major Project of China, No. 2018ZX10302206: collection of data; Ningbo Science and Technology Major Special Liver Disease Foundation, No. 2016C51008: collection of data; This work was supported by Chinese National Natural and Science Foundation, No. 81700552: analysis

Authors' contributions

Design of the study: Haihong Zhu, Yunyun Wang; Collection of data: Chao Chen, Yunyun Wang, Fengtian Wu, Lichen Xu, Jinjin Qi, Hanqin Cao, Guojun Li, Meng Hong; Analysis: Chunhong Huang, Ying Yang, Shanshan Wu; Interpretation of data: Haihong Zhu; Laboratory work: Fengtian Wu, Chao Chen, Yunyun Wang; Writing the manuscript: Yunyun Wang, Wei Lin

Acknowledgment
We would like to thank Yunxian Yu for the statistical consultation, thank http://www.letpub.com.cn for language edition.

References

1. Bernal W, Jalan R, Quaglia A, Simpson K, Wendon J, Burroughs A. Acute-on-chronic liver failure. *The Lancet*. 2015;386(10003):1576-1587.

2. Hernaez R, Sola E, Moreau R, Gines P. Acute-on-chronic liver failure: an update. *Gut*. 2017;66(3):541-553.

3. Li C, Zhu B, Lv S, You S, Xin S. Prediction model of the progression of patients with acute deterioration of hepatitis B virus-related chronic liver disease to acute-on-chronic liver failure. *Medicine (Baltimore)*. 2018;97(34):e11915.

4. Zhang GL, Zhang T, Zhao QY, Lin CS, Gao ZL. Th17 cells over 5.9% at admission indicate poor prognosis in patients with HBV-related acute-on-chronic liver failure. *Medicine (Baltimore)*. 2018;97(40):e12656.

5. Cai J, Wang K, Han T, Jiang H. Evaluation of prognostic values of inflammation-based markers in patients with HBV-related acute-on-chronic liver failure. *Medicine (Baltimore)*. 2018;97(46):e13324.

6. Kobayashi N, Ueno T, Ohashi K, Yamashita H, Takahashi Y, Sakamoto K, Manabe S, Hara S, Takashima Y, Dan T, Pastan I, Miyata T, Kurihara H, Matsusaka T, Reiser J, Nagata M. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated beta1-integrin endocytosis. *Am J Physiol Renal Physiol*. 2015;308(6):F614-626.

7. Genua M, D'Alessio S, Cibella J, Gandelli A, Sala E, Correale C, Spinelli A, Arena V, Malesci A, Rutella S, Ploplis VA, Vetrano S, Danese S. The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation. *Gut*. 2015;64(4):589-600.

8. Manetti M, Rosa I, Milia AF, Guiducci S, Carmeliet P, Ibba-Manneschi L, Matucci-Cerinic M. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? *Ann Rheum Dis*. 2014;73(9):1700-1709.

9. Mazzieri R, Pietrogrande G, Gerasi L, Gandelli A, Colombo P, Moi D, Brombin C, Ambrosi A, Danese S, Mignatti P, Blasi F, D'Alessio S. Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1. *Cancer Res*. 2015;75(22):4895-4909.

10. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. *Dis Markers*. 2009;27(3):157-172.

11. Sidenius N, Sier CF, Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. *FEBS Lett*. 2000;475(1):52-56.

12. Dande RR, Peev V, Altintas MM, Reiser J. Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus. *J Diabetes Res*. 2017;2017:3232848.
13. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. *Nat Rev Mol Cell Biol.* 2002;3(12):932-943.

14. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. *Nat Rev Mol Cell Biol.* 2010;11(1):23-36.

15. Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, Furie B, Furie BC, Cines DB, Huang M. Structure of human urokinase plasminogen activator in complex with its receptor. *Science.* 2006;311(5761):656-659.

16. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanachi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. *Nat Med.* 2011;17(8):952-960.

17. Abraham E, Gyetko MR, Kuhn K, Arcaroli J, Strassheim D, Park JS, Shetty S, Idell S. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. *J Immunol.* 2003;170(11):5644-5651.

18. Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts. *J Gastroenterol Hepatol.* 2011;26 Suppl 1:173-179.

19. Reyes-Gordillo K, Shah R, Muriel P. Oxidative Stress and Inflammation in Hepatic Diseases: Current and Future Therapy. *Oxid Med Cell Longev.* 2017;2017:3140673.

20. Taylor NJ, Manakkat Vijay GK, Abeles RD, Auzinger G, Bernal W, Ma Y, Wendon JA, Shawcross DL. The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality. *Aliment Pharmacol Ther.* 2014;40(6):705-715.

21. Donadello K, Scolletta S, Covajes C, Vincent JL. suPAR as a prognostic biomarker in sepsis. *BMC Med.* 2012;10:2.

22. Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, Chawla YK, Dokmeci AK, Garg H, Ghazinyan H, Hamid S, Kim DJ, Komolmit P, Lata S, Lee GH, Lesmana LA, Mahtab M, Maiwall R, Moreau R, Ning Q, Pamecha V, Payawal DA, Rastogi A, Rahman S, Rela M, Saraya A, Samuel D, Saraswat V, Shah S, Shiha G, Sharma BC, Sharma MK, Sharma K, Butt AS, Tan SS, Vashishthha C, Wani ZA, Yuen MF, Yokosuka O. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. *Hepatol Int.* 2014;8(4):453-471.

23. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. *Gut.* 2015;64(4):531-537.

24. Runyon BA. Management of adult patients with ascites due to cirrhosis. *Hepatology.* 2004;39(3):841-856.

25. Maras JS, Maiwall R, Harsha HC, Das S, Hussain MS, Kumar C, Bihari C, Rastogi A, Kumar M, Trehanpati N, Sharma S, Pandey A, Sarin SK. Dysregulated iron homeostasis is strongly associated
with multiorgan failure and early mortality in acute-on-chronic liver failure. *Hepatology.* 2015;61(4):1306-1320.

26. Wang Y, Chen C, Qi J, Wu F, Guan J, Chen Z, Zhu H. Altered PGE2-EP2 is associated with an excessive immune response in HBV-related acute-on-chronic liver failure. *J Transl Med.* 2019;17(1):93.

27. Shi Y, Yang Y, Hu Y, Wu W, Yang Q, Zheng M, Zhang S, Xu Z, Wu Y, Yan H, Chen Z. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. *Hepatology.* 2015;62(1):232-242.

28. Zimmermann HW, Reuken PA, Koch A, Bartneck M, Adams DH, Trautwein C, Stallmach A, Tacke F, Bruns T. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality. *J Intern Med.* 2013;274(1):86-100.

29. Koch A, Zimmermann HW, Gassler N, Jochum C, Weiskirchen R, Bruensing J, Buendgens L, Duckers H, Bruns T, Gerken G, Neumann UP, Adams DH, Trautwein C, Canbay A, Tacke F. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure. *Liver Int.* 2014;34(9):1330-1339.

30. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. *J Exp Med.* 1998;188(6):1029-1037.

31. Claria J, Arroyo V, Moreau R. The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray. *J Immunol.* 2016;197(10):3755-3761.

32. Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J. Soluble Urokinase Receptor and Chronic Kidney Disease. *N Engl J Med.* 2015;373(20):1916-1925.

33. Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J. Modification of kidney barrier function by the urokinase receptor. *Nat Med.* 2008;14(1):55-63.

34. Hahm E, Wei C, Fernandez I, Li J, Tardi NJ, Tracy M, Wadhwani S, Cao Y, Peev V, Zloza A, Lusciks J, Hayek SS, O’Connor C, Bitzer M, Gupta V, Sever S, Sykes DB, Scadden DT, Reiser J. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. *Nat Med.* 2017;23(10):1916-1925.

35. Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Lee H, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J. A tripartite complex of suPAR, APOL1 risk variants and alphavbeta3 integrin on podocytes mediates chronic kidney disease. *Nat Med.* 2017;23(8):945-953.

36. Sevgi DY, Bayraktar B, Gunduz A, Ozguven BY, Togay A, Bulut E, Uzun N, Dokmetas I. Serum soluble urokinase-type plasminogen activator receptor and interferon-gamma-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B. *Wien Klin Wochenschr.* 2016;128(1-2):28-33.
37. Sjowall C, Martinsson K, Cardell K, Ekstedt M, Kechagias S. Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. *Transl Res.* 2015;165(6):658-666.